Vol 91, No 1 (2020)
Review paper
Published online: 2020-01-31

open access

Page views 1963
Article views/downloads 2449
Get Citation

Connect on Social Media

Connect on Social Media

Human papilloma virus-related premalignant and malignant lesions of the cervix and anogenital tract in immunocompromised women

Aleksandra A. Wielgos1, Bronislawa Pietrzak2
Pubmed: 32039466
Ginekol Pol 2020;91(1):32-37.


The number of immunocompromised patients is rising, and immunodeficiency is an independent risk factor for the development of premalignant and malignant lesions of the cervix and anogenital tract. The aim of this review was to summarize and update data on human papilloma virus (HPV) infections and HPV-based anogenital lesions detected in patients who were immunocompromised due to both organ transplantation and human immunodeficiency virus (HIV) infection. The incidence of HPV infections among solid organ recipients and HIV positive females is reported to be significantly higher when compared with age-matched healthy controls- i.e. higher by up to 65% and 46.6% respectively, vs 38% in the controls. These infections are also more often chronic, high risk HPV and multitype. Data suggest that HPV infections in these patients might not only occur more frequently, but that the course of the infection might also lead to faster oncogenesis. However, the treatment options for malignancies are limited; and this implies the need for intense primary and secondary prevention regimens. As infections with HPV types other than 16 and 18 and multitype infections are particularly frequently discovered in immunocompromised patients, they would probably benefit most from a nonavalent vaccine. Gynecological screening should be performed annually, including cervical smears and/ or HPV testing. In the group of non-responders, self-sampling methods should be considered.

Article available in PDF format

View PDF Download PDF file


  1. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005; 80(2 Suppl): S254–S264.
  2. Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol. 2015; 42(2): 247–257.
  3. Meeuwis KAP, van Rossum MM, van de Kerkhof PCM, et al. Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients. Transpl Int. 2010; 23(2): 191–199.
  4. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338(7): 423–428.
  5. Hinten F, Meeuwis KAP, van Rossum MM, et al. HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients. Crit Rev Oncol Hematol. 2012; 84(2): 161–180.
  6. Cespedes MS, Kang M, Kojic EM, et al. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res. 2018; 6: 15–21.
  7. Looker KJ, Rönn MM, Brock PM, et al. Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Soc. 2018; 21(6): e25110.
  8. Clifford GM, de Vuyst H, Tenet V, et al. Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. J Acquir Immune Defic Syndr. 2016; 73(3): 332–339.
  9. Brown MR, Noffsinger A, First MR, et al. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. Gynecol Oncol. 2000; 79(2): 220–224.
  10. Blitz S, Baxter J, Raboud J, et al. Canadian Women's HIV Study Group. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis. 2013; 208(3): 454–462.
  11. Meeuwis KAP, Melchers WJG, Bouten H, et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation. 2012; 93(9): 914–922.
  12. Adebamowo SN, Olawande O, Famooto A, et al. H3Africa ACCME Research Group. Persistent Low-Risk and High-Risk Human Papillomavirus Infections of the Uterine Cervix in HIV-Negative and HIV-Positive Women. Front Public Health. 2017; 5: 178.
  13. Pietrzak B, Mazanowska N, Ekiel AM, et al. Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients: an observational study. Virol J. 2012; 9: 117.
  14. Origoni M, Stefani C, Dell'Antonio G, et al. Cervical Human Papillomavirus in transplanted Italian women: a long-term prospective follow-up study. J Clin Virol. 2011; 51(4): 250–254.
  15. Hampl M, Wentzensen N, Vinokurova S, et al. Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol. 2007; 133(4): 235–245.
  16. Snijders PJF, Steenbergen RDM, Heideman DAM, et al. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006; 208(2): 152–164.
  17. Banura C, Sandin S, van Doorn LJ, et al. Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Infect Agent Cancer. 2010; 5: 7.
  18. Meeuwis KAP, Hilbrands LB, IntHout J, et al. Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based, cohort study. Am J Transplant. 2015; 15(3): 723–733.
  19. Mazanowska N, Szpotańska-Sikorska M, Madej A, et al. Prevalence of Cervical Infection With Human Papillomavirus of High Oncogenic Potential in Immunosuppressed Women on Renal Replacement Therapy With and Without Mammalian Target of Rapamycin Inhibitors. Transplant Proc. 2018; 50(6): 1889–1891.
  20. Madeleine MM, Finch JL, Lynch CF, et al. HPV-related cancers after solid organ transplantation in the United States. Am J Transplant. 2013; 13(12): 3202–3209.
  21. Tanaka Y, Ueda Y, Kakuda M, et al. Clinical outcomes of abnormal cervical cytology and human papillomavirus-related lesions in patients with organ transplantation: 11-year experience at a single institution. Int J Clin Oncol. 2016; 21(4): 730–734.
  22. Stier EA, Baranoski AS. Human papillomavirus-related diseases in HIV-infected individuals. Curr Opin Oncol. 2008; 20(5): 541–546.
  23. Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018; 32(6): 795–808.
  24. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007; 99(12): 962–972.
  25. Nissen NN, Barin B, Stock PG. Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol. 2012; 24(5): 517–521.
  26. Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014; 59(1): 127–135.
  27. Roensbo MT, Blaakaer J, Skov K, et al. Cervical HPV prevalence and genotype distribution in immunosuppressed Danish women. Acta Obstet Gynecol Scand. 2018; 97(2): 142–150.
  28. Nega AD, Woldetsadik MA, Gelagay AA. Low uptake of cervical cancer screening among HIV positive women in Gondar University referral hospital, Northwest Ethiopia: cross-sectional study design. BMC Womens Health. 2018; 18(1): 87.
  29. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000; 11 Suppl 15: S1–86.
  30. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant. 2002; 17 Suppl 4: 32, 34–6.
  31. Kerkhoff BA, O'Connor TCF, Plant WD, et al. Poor uptake of reproductive health screening services by female renal transplant recipients. Ir Med J. 2006; 99(3): 78–80.
  32. Courtney AE, Leonard N, O'Neill CJ, et al. The uptake of cervical cancer screening by renal transplant recipients. Nephrol Dial Transplant. 2009; 24(2): 647–652.
  33. van Baars R, Bosgraaf RP, ter Harmsel BWA, et al. Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women. J Clin Microbiol. 2012; 50(12): 3937–3943.
  34. Stanczuk G, Baxter G, Currie H, et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open. 2016; 6(4): e010660.
  35. Liao JB, Fisher CE, Madeleine MM. Gynecologic cancers and solid organ transplantation. Am J Transplant. 2019; 19(5): 1266–1277.